Christine Jessop’s killer identified: Solved cold case raises questions about genetic privacy
By Julia Creet,
The Conversation
| 10. 22. 2020
On Oct. 15, Toronto police announced that they had finally solved the 1984 murder of Christine Jessop using DNA evidence and genetic genealogy websites. Identifying Calvin Hoover as Jessop’s killer has provided immense relief to the family and those close to the case, and in particular to Guy Paul Morin, who was wrongfully convicted and later exonerated after serving 18 months in prison.
The announcement highlights a conundrum: at risk is the genetic privacy of everyone who has uploaded — and, mostly, not uploaded — a DNA sample to a commercial genealogy site.
Genealogists never anticipated that their benign but passionate interest in tracking relations through records and DNA would ever lead to law enforcement’s most potent cold case tool kit. In 2018, public awareness of law enforcement’s mining of genetic genealogy came to light with the 2018 identification of the Golden State Killer. The identification of Joseph James DeAngelo relied on freely uploaded DNA results alongside painstaking genealogical research.
Data industry
Since then, law enforcement’s mining of genealogical data has become an industry in itself, with hundreds...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...